Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
ipilimumab based treatment ipilimumab alone ipilimumab based treatment anti-CTLA-4 ipilimumab alone Ipilimumab (10 mg/kg) ipilimumab plus gp100 ipilimumab plus SoC tremelimumab mML - (neo)adjuvant (NA) mML - NA - all population 9 mML - NA - PDL1 positive 1 mML - 1st line (L1) mML - L1 - all population 7 mML - L1 - BRAF mutant 2 mML - L1 - BRAF wild 3 mML - 2nd line (L2) mML - L2 - all population 11 mML - L2 - BRAF mutant 1
Comparator:
vs Standard of Care (SoC); vs ipilimumab alone; vs gp100; vs placebo plus SoC; vs interferon alpha; vs placebo;
Risk of bias:
low;
some concerns;
high;
NA;